Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Telitacicept in early-stage primary Sjögren’s syndrome
ChiCTR2500107782Phase 4Not yet recruiting
- Sponsor
- First Affiliated Hospital of Kunming Medical University
- Start
- Aug 2025
- Modality
- Fc-Fusion Proteins → Carrier/Scaffold Proteins → Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 4, randomised, double-blind trial in primary Sjögren's syndrome comparing Telitacicept group with Placebo/conventional therapy group (2 arms). Primary endpoint: Between-group difference in change from baseline in ESSDAI score at Week 24. Planned start Aug 2025; status: not yet recruiting.
02
Drugs
telitacicept
03
Conditions
primary Sjögren's syndrome
Beyond the preview
Go deeper on ChiCTR2500107782.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2500107782.